Study evaluates Hepatitis C cost burden
The data demonstrated that the costs related to managing hepatitis C involve more than specialty drug expenses.
“This data clearly explains why the cost challenges experienced by payers will not be mitigated by prior authorization and other tactics that focus on new specialty drugs alone,” Primrose Healthcare CEO Henri Cournand said. “While drug costs dominate the headlines and today’s research around HCV, there is a much more compelling argument to be made that improving the holistic management of this condition is the most effective cost control strategy.”
The study, titled “The burden of hepatitis C virus (HCV) disease in commercial and managed Medicaid populations,” evaluated a wide range of the factors that affect the outcomes and cost connected to hepatitis C patients. There is a variety of health care services that people with hepatitis C infections use.
“While many payers are focused on addressing the financial burden of new drug treatments for Hepatitis C, they may be missing a bigger picture perspective on the underlying cost drivers within these populations,” Helen Blumen, principal and healthcare management consultant for Milliman, said. “The health care system must zero in on interventions that optimize the patient’s liver health while addressing both HCV and comorbidities that lead to disease progression and poor outcomes in the long term.”